Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction

Sager, Cristian; Sanmartino, Marianela; Burek, Carol; Gomez, Yesica; Patiño, Mariana Vazquez; Weller, Santiago; Ruiz, Javier; Imizcoz, Felicitas Lopez; Tessi, Catalina; Szklarz, Tatiana; Corbetta, Juan Pablo

doi:10.1016/j.jpurol.2020.07.020

Cited by 12 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In children with neurogenic bladder refractory to first and second-line therapies, mirabegron, as an adjuvant, increases bladder capacity, reduces intravesical pressure and achieves continence in a great number of patients. It is a well-tolerated drug, with no adverse effects, which implies reducing or postponing the need for bladder augmentation (92).…”

Section: ß3 Adrenoceptor Agonistsmentioning

confidence: 99%

Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment

Sager¹,

Barroso

Bastos

et al. 2022

Int. braz j urol.

Self Cite

View full text Add to dashboard Cite

Introduction: Defective closure of the neural tube affects different systems and generates sequelae, such as neurogenic bladder (NB). Myelomeningocele (MMC) represents the most frequent and most severe cause of NB in children. Damage of the renal parenchyma in children with NB acquired in postnatal stages is preventable given adequate evaluation, follow-up and proactive management. The aim of this document is to update issues on medical management of neurogenic bladder in children. Materials and Methods: Five Pediatric Urologists joined a group of experts and reviewed all important issues on "Spina Bifi da, Neurogenic Bladder in Children" and elaborated a draft of the document. All the members of the group focused on the same system of classifi cation of the levels of evidence (GRADE system) in order to assess the literature and the recommendations. During the year 2020 the panel of experts has met virtually to review, discuss and write a consensus document. Results and Discussion: The panel addressed recommendations on up to date choice of diagnosis evaluation and therapies. Clean intermittent catheterization (CIC) should be implemented during the fi rst days of life, and antimuscarinic drugs should be indicated upon results of urodynamic studies. When the patient becomes refractory to fi rst-line therapy, receptor-selective pharmacotherapy is available nowadays, which leads to a reduction in reconstructive procedures, such as augmentation cystoplasty.

show abstract

Section: ß3 Adrenoceptor Agonistsmentioning

confidence: 99%

Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment

Sager¹,

Barroso

Bastos

et al. 2022

Int. braz j urol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 272,273 ] A number of treatments, ranging from medications to surgical interventions, have been developed with the hope of treating this condition. [ 274–278 ] However, due to the fact that neurogenic bladder dysfunction can arise from a number of conditions, including Parkinson's Disease, stroke, brain injury, and multiple sclerosis, developing a universal treatment for this condition remains a challenge. [ 279 ] Neurogenic bladder dysfunction has differing results which can range from an overactive bladder, to difficulty passing urine.…”

Section: Neural Engineeringmentioning

confidence: 99%

Triboelectric Nanogenerators for Therapeutic Electrical Stimulation

et al. 2021

View full text Add to dashboard Cite

Current solutions developed for the purpose of in and on body (IOB) electrical stimulation (ES) lack autonomous qualities necessary for comfortable, practical, and self‐dependent use. Consequently, recent focus has been placed on developing self‐powered IOB therapeutic devices capable of generating therapeutic ES for human use. With the recent invention of the triboelectric nanogenerator (TENG), harnessing passive human biomechanical energy to develop self‐powered systems has allowed for the introduction of novel therapeutic ES solutions. TENGs are especially effective at providing ES for IOB therapeutic systems given their bioconformability, low cost, simple manufacturability, and self‐powering capabilities. Due to the key role of naturally induced electrical signals in many physiological functions, TENG‐induced ES holds promise to provide a novel paradigm in therapeutic interventions. The aim here is to detail research on IOB TENG devices applied for ES‐based therapy in the fields of regenerative medicine, neurology, rehabilitation, and pharmaceutical engineering. Furthermore, considering TENG‐produced ES can be measured for sensing applications, this technology is paving the way to provide a fully autonomous personalized healthcare system, capable of IOB energy generation, sensing, and therapeutic intervention. Considering these grounds, it seems highly relevant to review TENG‐ES research and applications, as they could constitute the foundation and future of personalized healthcare.

show abstract

“…The same study found no significant differences between oxybutynin, which has the most supporting data, and other anticholinergic agents [ 20 ]. Mirabegron, a beta-3 adrenergic receptor agonist, also decreases detrusor activation and has shown promising improvements in urgency and frequency when used as a second-line treatment after antimuscarinic medications [ 24 ]. Mirabegron also has the advantage of a more favorable side effect profile, but is not likely to overtake antimuscarinics as the first-line treatment until more large RCTs are available [ 25 ].…”

Section: Current Treatmentsmentioning

confidence: 99%

Spinal cord injury and neurogenic lower urinary tract dysfunction: what do we know and where are we going?

Dodd¹,

Motwani²,

Small³

et al. 2022

JOMH

View full text Add to dashboard Cite

One of the well reported but difficult to manage symptoms of spinal cord injury (SCI) is neurogenic lower urinary tract dysfunction (NLUTD). The type of NLUTD is variable based on location and extent of injury. SCI affects more males and NLUTD is especially debilitating for men with incomplete injury. This review summarizes the anatomical basis of NLUTD in SCI and discusses current diagnostic and management strategies that are being utilized clinically. The last two sections address new innovations and emerging discoveries with the goal of increasing scientific interest in improving treatment options for people with SCI. Areas warranting further investigation are pinpointed to address current gaps in knowledge and/or appropriate technology.

show abstract

Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction

Cited by 12 publications

References 20 publications

Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment

Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment

Triboelectric Nanogenerators for Therapeutic Electrical Stimulation

Spinal cord injury and neurogenic lower urinary tract dysfunction: what do we know and where are we going?

Contact Info

Product

Resources

About